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Effect of Continuous Glucose Monitoring on Glycemic Control
in Adults With Type 1 Diabetes Using Insulin Injections
The DIAMOND Randomized Clinical Trial
Roy W. Beck, MD, PhD; Tonya Riddlesworth, PhD; Katrina Ruedy, MSPH; Andrew Ahmann, MD;
Richard Bergenstal, MD; Stacie Haller, RD, LD, CDE; Craig Kollman, PhD; Davida Kruger, MSN, APN-BC;
Janet B. McGill, MD; William Polonsky, PhD; Elena Toschi, MD; Howard Wolpert, MD; David Price, MD;
for the DIAMOND Study Group
Editorial page 363
IMPORTANCE Previous clinical trials showing the benefit of continuous glucose monitoring

Related article page 379

(CGM) in the management of type 1 diabetes predominantly have included adults using
insulin pumps, even though the majority of adults with type 1 diabetes administer insulin
by injection.

Supplemental content

OBJECTIVE To determine the effectiveness of CGM in adults with type 1 diabetes treated with
insulin injections.
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CME Questions page 436

DESIGN, SETTING, AND PARTICIPANTS Randomized clinical trial conducted between October
2014 and May 2016 at 24 endocrinology practices in the United States that included 158
adults with type 1 diabetes who were using multiple daily insulin injections and had
hemoglobin A1c (HbA1c) levels of 7.5% to 9.9%.
INTERVENTIONS Random assignment 2:1 to CGM (n = 105) or usual care (control group; n = 53).
MAIN OUTCOMES AND MEASURES Primary outcome measure was the difference in change
in central-laboratory–measured HbA1c level from baseline to 24 weeks. There were
18 secondary or exploratory end points, of which 15 are reported in this article, including
duration of hypoglycemia at less than 70 mg/dL, measured with CGM for 7 days at 12
and 24 weeks.
RESULTS Among the 158 randomized participants (mean age, 48 years [SD, 13]; 44% women;
mean baseline HbA1c level, 8.6% [SD, 0.6%]; and median diabetes duration, 19 years
[interquartile range, 10-31 years]), 155 (98%) completed the study. In the CGM group, 93%
used CGM 6 d/wk or more in month 6. Mean HbA1c reduction from baseline was 1.1% at 12
weeks and 1.0% at 24 weeks in the CGM group and 0.5% and 0.4%, respectively, in the
control group (repeated-measures model P < .001). At 24 weeks, the adjusted
treatment-group difference in mean change in HbA1c level from baseline was –0.6% (95% CI,
–0.8% to –0.3%; P < .001). Median duration of hypoglycemia at less than <70 mg/dL was
43 min/d (IQR, 27-69) in the CGM group vs 80 min/d (IQR, 36-111) in the control group
(P = .002). Severe hypoglycemia events occurred in 2 participants in each group.
CONCLUSIONS AND RELEVANCE Among adults with type 1 diabetes who used multiple daily
insulin injections, the use of CGM compared with usual care resulted in a greater decrease in
HbA1c level during 24 weeks. Further research is needed to assess longer-term effectiveness,
as well as clinical outcomes and adverse effects.
TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT02282397
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O

nly approximately 30% of individuals with type 1 diabetes meet the American Diabetes Association goal of
hemoglobin A1c (HbA1c) level of 7.5% (58 mmol/mol)
for children (<18 years) and 7.0% (53 mmol/mol) for adults
(≥18 years),1 indicating the need for better approaches to diabetes management. Continuous glucose monitoring (CGM)
with glucose measurements as often as every 5 minutes, plus
low and high glucose level alerts and glucose trend information, has the capability of better informing diabetes management decisions than blood glucose meter testing performed
several times a day. Randomized clinical trials have demonstrated the benefit of CGM in adults with type 1 diabetes, but
not consistently in children, to improve glycemic control as
measured by HbA1c level and to reduce hypoglycemia.2-6 These
previous trials have either completely or predominantly included insulin pump users,2,4,5 although the majority of adults
with type 1 diabetes deliver insulin via injections.7,8
Only a small proportion of individuals with type 1 diabetes who inject insulin use CGM, although the limited available observational data suggest that the glycemic benefit may
be comparable to that for pump users. In T1D Exchange registry 2015 data, mean HbA1c level in the 410 adult insulin injecters using CGM was similar to that in 2316 pump users using
CGM (7.6% vs 7.7%, respectively) and lower than mean HbA1c
level in the 6222 injection users not using CGM (7.6% vs 8.8%;
P < .001).9
Whether individuals receiving insulin injections would be
willing to regularly wear CGM sensors and would derive glycemic benefits from CGM needs investigation. Accordingly, this randomized multicenter clinical trial was conducted to evaluate the
effect of CGM in adults with type 1 diabetes who have elevated
HbA1c levels and use multiple daily injections of insulin.

Methods
The trial was conducted at 24 endocrinology practices in the
United States (19 community-based and 5 academic centers).
The protocol and Health Insurance Portability and Accountability Act–compliant informed consent forms were approved by institutional review boards (central commercial
board for 17 sites and local boards for the other 7 sites). Written
informed consent was obtained from each participant. The protocol is provided online and the statistical analysis plan is available in Supplement 1.

Study Participants
Major eligibility criteria included age 25 years or older, diagnosis of type 1 diabetes treated for at least 1 year with multiple daily
insulin injections, central laboratory–measured HbA1c level of
7.5% to 10.0%, no home use of a personal CGM device in the 3
months before the trial, and a negative pregnancy test for women of childbearing potential (eTable 1 in Supplement 2 has a complete listing of the inclusion and exclusion criteria).

Synopsis of Study Design
Each participant was required to complete a 2-week prerandomization phase using a CGM system that was configured to
372

Key Points
Question For adults with type 1 diabetes who are using multiple
daily insulin injections, does continuous glucose monitoring
improve hemoglobin A1c (HbA1c) levels compared with
self-monitored blood glucose management?
Findings In a randomized clinical trial of 158 adults with type 1
diabetes, there was a significantly greater decrease in HbA1c level
during 24 weeks with continuous glucose monitoring vs usual care
(–1.0% vs –0.4%).
Meaning Continuous glucose monitoring resulted in better
glycemic control compared with usual care, but further research
is needed to assess clinical outcomes, as well as effectiveness,
in a typical clinical population.

record glucose concentrations not visible to the participant
(referred to as a “blinded” CGM). Eligibility required that the
blinded CGM be worn on at least 85% of possible days, the
CGM be calibrated at least 2 times per day, and blood glucose
meter testing (with a study-provided meter and test strips) be
performed at least 3 times daily. Fourteen participants did
not meet these criteria and did not continue into the randomized trial (Figure 1). One participant had a sudden death during the prerandomization phase.
On the study website, after verification of eligibility
from data entered, each participant was assigned randomly
from a computer-generated sequence to either the CGM or control group in a 2:1 ratio, with a permuted block design (block
sizes of 3 and 6) stratified by HbA1c level (<8.5% and ≥8.5%).
A 2:1 randomization was used rather than 1:1 to provide a larger
sample size for a separate follow-on randomized trial assessing glycemic benefits of initiating pump therapy in CGM
users using insulin injections.
Participants in the CGM group were provided with a CGM
system (Dexcom G4 Platinum CGM System with an enhanced
algorithm, software 505, Dexcom Inc) that measured glucose
concentrations from interstitial fluid in the range of 40 to
400 mg/dL every 5 minutes for up to 7 days. Participants in
both groups were provided with a Bayer Contour Next USB
meter and test strips. The CGM group was instructed to use
the CGM daily, calibrate the CGM twice daily, and verify the
CGM glucose concentration with the blood glucose meter
before injecting insulin (as per the regulatory labeling of the
device at the time the trial was conducted). General guidelines were provided to participants about using CGM, and
individualized recommendations were made by their clinician about incorporating CGM trend information into their
diabetes management. The control group was asked to perform home blood glucose monitoring at least 4 times daily.
Participants in both groups were provided general diabetes
management education, and clinicians were encouraged to
review downloaded glucose data at each visit to inform treatment recommendations, which were at clinician discretion
and not prescriptive in the protocol. eTable 2 in Supplement 2
describes the participant education as well as guidelines for
clinicians. CGM guidelines for participants are included in
Supplement 1.
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Follow-up visits for both treatment groups occurred
after 4, 12, and 24 weeks. The CGM group had an additional
visit 1 week after randomization. The control group had 2
additional visits 1 week before the 12- and 24-week visits, at
which a CGM sensor in blinded mode was inserted to collect
glucose data for 1 week. Telephone contacts for both groups
occurred 2 and 3 weeks after randomization.
Hemoglobin A 1c level was measured at baseline, 12
weeks, and 24 weeks at the Northwest Lipid Research Laboratories, University of Washington, Seattle, with the Diabetes
Control and Complications Trial standardized analyzer
(TOSOH, Biosciences Inc).

Outcomes
The primary outcome was change in the central laboratory–
measured HbA 1c level. Prespecified secondary outcomes
included percentage of participants with HbA1c level less than
7.0%; CGM-measured time in range (70-180 mg/dL), duration
of hypoglycemia (<70 mg/dL, <60 mg/dL, and <50 mg/dL),
duration of hyperglycemia (>180 mg/dL, >250 mg/dL, and
>300 mg/dL), and glucose variability (coefficient of variation); change in hypoglycemia unawareness10; and change in
frequency of blood glucose meter testing (longitudinal
changes in blood glucose meter testing were not assessed).
Prespecified exploratory outcomes included CGM-measured
mean glucose concentration and the following binary HbA1c
outcomes to assist in translation of the primary HbA1c analysis to a participant level: HbA1c level less than 7.5% and relative HbA1c reduction greater than or equal to 10%. Post hoc
outcomes included HbA1c reduction of 1% or more, HbA1c
level less than 7.0% or reduction of 1% or more, CGMmeasured area above the curve 70 mg/dL and area under
the curve 180 mg/dL, change in insulin dose, and change in
body weight.
Satisfaction with CGM was assessed by completion at 24
weeks of the CGM Satisfaction Survey (44 items on a 1-5
Likert scale, with the computed score representing the
mean of the 44 items and subscales of benefits and lack of
hassles).11 Quality-of-life and health economic outcomes
will be reported in separate articles.
Safety outcomes included severe hypoglycemia (defined
as an event that required assistance from another person
to administer carbohydrate, glucagon, or other resuscitative
actions), diabetic ketoacidosis, and serious adverse events regardless of causality.

Statistical Methods
A sample size of 147 for the 2:1 randomization was calculated
to have 90% power to detect a difference in mean HbA1c
level between treatment groups, assuming a population difference of 0.4%, standard deviation of the 24-week values of
0.7 adjusted for the correlation between baseline and
24-week values (based on data from the Juvenile Diabetes
Research Foundation CGM randomized trial5), and a 2-sided
α level of .05. Sample size initially was increased to 169 to
account for potential loss to follow-up. When it was recognized by the coordinating center that the trial completion
rate was higher than anticipated, the recruitment goal was

Original Investigation Research

Figure 1. Flowchart of Continuous Glucose Monitoring Study Completion
186 Patients enrolled
28 Excluded during
prerandomization phase
14 Did not meet run-in
eligibility for continuous
glucose monitoring and/or
blood glucose meter
8 Requested to withdraw
5 Had HbA1c <7.5% or >10%
1 Died
158 Randomized

105 Randomized to receive continuous
glucose monitoring system

53 Randomized to receive usual
care (control)

3 Discontinued study
1 Lost to follow up
1 Site withdrew participant
1 Participant requested to
withdraw
102 Completed the study
2 Completed study but
discontinued continuous
glucose monitoring

53 Completed the study

105 Included in primary analysis
4 Imputation used for HbA1c value

53 Included in primary analysis

All enrolled participants started the run-in phase; 28 did not proceed to
randomization for the reasons indicated in the figure. The number eligible for
screening who did not sign the informed consent form was not recorded.

changed to a minimum of 150, with the approval of the steering committee and the sponsor.
Analyses followed the intent-to-treat principle. The following change was made from the protocol and statistical
analysis plan before the data lock: the primary analysis was
a treatment group comparison of the change in HbA1c level
from baseline to 24 weeks, adjusted for baseline HbA 1c
level and clinical site as a random effect, in a repeatedmeasures linear model in the protocol and with analysis of
covariance in the statistical analysis plan; both are reported
in this article. Confounding was assessed by repeating the
analysis, including potential confounding variables as covariates. The Rubin method was used to impute for missing
data.12 Exploratory analyses were conducted to assess for
interaction between the treatment effect on the change in
HbA1c level from baseline to 24 weeks and baseline factors by
including interaction terms in analysis of covariance models.
The following changes were made from the protocol and statistical analysis plan during the peer-review process: in post
hoc analyses, binary HbA1c outcomes were evaluated with
propensity scores13 instead of logistic regression, adjusted for
baseline HbA 1c level and clinical site; and for secondary,
exploratory, and post hoc analyses, 99% CIs instead of 95%
CIs are reported.
For CGM outcomes, treatment group comparisons using
the CGM data collected in each group for 7 days at 12 and 24
weeks were made with analysis of covariance models based
on ranks using van der Waerden scores if the metric was
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Table 1. Baseline Participant Characteristics
Group, No. (%)
CGM
(n = 105)

Control
(n = 53)

25-<45

53 (50)

16 (30)

45-<60

32 (30)

23 (43)

≥60

20 (19)

14 (26)

Mean (SD) [range]

46 (14)
[26-72]

51 (11)
[26-73]

Diabetes duration, median (IQR), y

19 (9-29)

19 (11-35)

Female sex

47 (45)

23 (43)

Age, y

Highest educationa
<Bachelor’s degree

47 (47)

22 (43)

Bachelor's degree

43 (43)

19 (37)

10 (10)

10 (20)

BMI, mean (SD)

Graduate degree

28 (6)

27 (5)

Weight, mean (SD), kg

84 (20)

81 (18)

47 (45)

24 (45)

HbA1c, %
7.5-<8.5
8.5-≤9.9

58 (55)

29 (55)

Mean (SD) [range]

8.6 (0.7)
[7.5-9.9]

8.6 (0.6)
[7.5-9.9]

Self-reported No. of self-monitoring
blood glucose tests per day,
mean (SD)

3.9 (1.3)

4.1 (1.6)

Event in previous 12 mo
≥1 Severe hypoglycemia

8 (8)

9 (17)

≥1 Diabetic ketoacidosis

1 (<1)

1 (2)

Use of noninsulin glucose-lowering
medication

8 (8)

4 (8)

Total daily insulin dose, median (IQR),
U/kg/d

0.7 (0.5-0.9)

0.6 (0.5-0.9)

No. of long-acting insulin injections
per day
1

78 (74)

34 (64)

2

26 (25)

19 (36)

3

1 (<1)

0

No. of rapid-acting insulin injections
per day
2

0

1 (2)

3

71 (68)

32 (60)

4

23 (22)

15 (28)

≥5

11 (10)

5 (9)

17 (16)

9 (17)

CGM use previously

Abbreviations: BMI, body mass index (calculated as weight in kilograms divided
by height in meters squared); CGM, continuous glucose monitoring; HbA1c,
hemoglobin A1c; IQR, interquartile range.
SI Conversions: to convert HbA1c to the SI units of mmol/mol, multiply the HbA1c
percentage value × 10.93 and subtract 23.5 from the product.
a

Statistical methods for other analyses are described in table
footnotes. Standard deviations are reported for means and interquartile ranges (IQRs) for medians where applicable. Reported point estimates are unadjusted unless otherwise noted.
Analyses were conducted with SAS version 9.4. All P values
are 2 sided. P < .05 was considered significant for the primary analysis and P < .01 for all other analyses to account for
multiple comparisons (with 99% CIs accordingly provided).

SI Unit Conversions
Throughout, to convert HbA1c to the SI units of mmol/mol, multiply the HbA1c percentage value × 10.93 and subtract 23.5 from
the product. For example, an HbA 1c value of 7.0% corresponds to 53 mmol/mol. To convert glucose to mmol/L, multiply the values × 0.0555.

Results
Between October 2014 and December 2015, 158 participants
were assigned to the CGM group (n = 105) or control group
(n = 53). Mean age was 48 years (SD, 13) (range, 26-73 years,
with 34 participants [22%] ≥60 years); 44% were women. Median diabetes duration was 19 years (IQR, 10-31 years), and
mean baseline HbA1c level was 8.6% (SD, 0.6%; range, 7.5%9.9%). Participant characteristics according to randomized
group are shown in Table 1.
The 24-week primary study outcome visit was completed by 102 participants (97%) in the CGM group and all 53
(100%) in the control group (Figure 1). Overall visit completion was 99% and 98%, respectively. Three participants in the
CGM group (4 total visits) and 3 in the control group (3 total
visits) had additional visits, not required in the protocol, for
diabetes management.
Among the 102 participants in the CGM group who completed the trial, median CGM use was 7.0 d/wk (IQR, 7.0-7.0)
at 4, 12, and 24 weeks; only 2 (2%) discontinued CGM before
the 24-week visit. During month 6 (weeks 21-24), CGM use was
6 or more d/wk for 93% of the 102 participants (eTable 3 in
Supplement 2). No participant in the control group initiated
unblinded CGM use before the primary outcome.
According to meter downloads, mean blood glucose selfmonitoring was 5.1 tests per day (SD, 1.8) in the CGM group and
5.1 tests per day (SD, 1.4) in the control group during the baseline period of blinded CGM wear and 3.6 tests per day (SD, 1.6)
and 4.6 tests per day (SD, 1.6), respectively, at 24 weeks
(adjusted mean difference for the change, –1.0; 99% CI, –1.7 to
–0.4; P < .001).

Education data missing for 5 in the CGM group and 2 in the control group.

Glycemic Control and Other Outcomes
skewed, adjusted for the corresponding baseline value, baseline HbA1c level, and clinical site as a random effect. Similar
analyses were performed separately for daytime and nighttime. Frequency of blood glucose monitoring was compared
between groups with an analysis of covariance model, adjusted for the baseline frequency and clinical site as a random effect.
374

Primary Outcome
Mean reduction in HbA1c level from baseline was 1.1% at
12 weeks and 1.0% at 24 weeks in the CGM group and 0.5% and
0.4%, respectively, in the control group (primary analysis repeated-measures P < .001). At 24 weeks, the adjusted treatment group difference in mean change in HbA1c level was –0.6%
(95% CI, –0.8% to –0.3%; P < .001) (Table 2). For each treatment group, baseline and 24-week HbA1c values for each
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Table 2. Primary Outcome and Hemoglobin A1c Outcomes at 12 and 24 Weeksa
12 Weeks

24 Weeks
Control
Group
(n = 52)

CGM Group
(n = 103)

CGM Group
(n = 105)b

Control
Group
(n = 53)

Between-Group Differencec,d

Primary outcome, mean (SD), %

P Valuec,d

Mean adjusted difference, % (95% CI)

HbA1c
Change in HbA1c from baseline

7.6 (0.7)

8.1 (0.7)

7.7 (0.8)

8.2 (0.8)

−1.1 (0.7)

−0.5 (0.7)

−1.0 (0.8)

−0.4 (0.7)

Prespecified secondary outcome, No. (%)
HbA1c <7.0%

−0.6 (−0.8 to −0.3)

<.001

Mean adjusted difference, % (99% CI)
14 (14)

2 (4)

18 (18)

2 (4)

15 (0 to 30)

.01

Prespecified exploratory outcomes, No. (%)
HbA1c <7.5%

49 (48)

6 (12)

39 (38)

6 (11)

31 (12 to 51)

<.001

Relative reduction in HbA1c ≥10%

62 (60)

12 (23)

58 (57)

10 (19)

37 (16 to 58)

<.001

Post hoc outcomes, No. (%)
Reduction in HbA1c ≥1%

55 (53)

12 (23)

53 (52)

10 (19)

33 (11 to 54)

<.001

Reduction in HbA1c ≥1% or HbA1c <7.0%

57 (55)

12 (23)

53 (52)

11 (21)

31 (9 to 52)

<.001

missing (3 in the CGM group and 0 in the control group). For the secondary,
exploratory, and post hoc analyses, n = 102.

Abbreviations: CGM, continuous glucose monitoring; HbA1c, hemoglobin A1c.
SI Conversion: to convert HbA1c to the SI units of mmol/mol, multiply the HbA1c
percentage value × 10.93 and subtract 23.5 from the product.
a

b

Mean baseline HbA1c level was 8.6% in each group. For all analyses,
missing HbA1c values in which the central laboratory value was missing
but the local laboratory value was known were imputed with a regression line
based on the site’s local HbA1c measurements (CGM/control: 1/0 at 12 weeks;
1/0 at 24 weeks).
For the 24-week primary outcome only, the Rubin method was used to impute
missing HbA1c values when both the central and local laboratory values were

c

For the primary analysis, treatment group comparisons were made with
analysis of covariance models, adjusted for baseline HbA1c level and clinical
site as a random effect. Model residuals were verified to have an approximate
normal distribution.

d

For the secondary, exploratory, and post hoc outcomes, treatment group
comparisons were made with propensity scores, adjusted for baseline HbA1c
level and clinical site. P < .01 was considered significant to account for multiple
comparisons (with 99% CIs accordingly provided).

Figure 2. Hemoglobin A1c Values at Baseline and 24 Weeks, by Group
A HbA1c at baseline and 24 weeks

B

11

Cumulative distribution of HbA1c at 24 weeks
100
CGM (n = 102)
80

Cumulative Distribution

10

HbA1c at 24 Weeks, %

90

CGM (n = 102)
Control (n = 53)

9

8

7

Control (n = 53)

70
60
50
40
30
20

6

10
5
5

6

7

8

9

10

0
≤5

Baseline HbA1c, %

≤6

≤7

≤8

≤9

≤10

HbA1c at 24 Weeks, %

A, Scatterplot of 24-week hemoglobin A1c (HbA1c) levels by baseline HbA1c level.
The horizontal line at 7.0% represents the American Diabetes Association HbA1c
goal for adults with type 1 diabetes. Points below the diagonal line represent
cases in which the 24-week HbA1c level was lower than the baseline HbA1c level,
points above the diagonal line represent cases in which the 24-week HbA1c level
was higher than the baseline HbA1c level, and points on the diagonal line

represent cases in which the 24-week and baseline HbA1c values were the same.
B, Cumulative distribution of 24-week HbA1c values. For any given 24-week
HbA1c level, the percentage of cases in each treatment group with an HbA1c
value at that level or lower can be determined from the figure. To convert HbA1c
to the SI units of mmol/mol, multiply the HbA1c percentage value × 10.93 and
subtract 23.5 from the product.

participant are shown in Figure 2A, and the cumulative distribution of the 24-week HbA1c values is shown in Figure 2B.

interaction of the effect of treatment on 24-week HbA1c level
according to baseline HbA1c, age, education level, or type of
site (eTable 4 in Supplement 2).

Secondary, Exploratory, and Post Hoc HbA1c Outcomes
The greater HbA1c improvement in the CGM group also was reflected in multiple participant-level secondary, exploratory, and
post hoc HbA1c outcomes (Table 2). There was no significant

Secondary and Exploratory CGM Outcomes
As secondary outcomes, CGM metrics for time in the range of
70 to 180 mg/dL, hyperglycemia, hypoglycemia, and glycemic
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Table 3. Continuous Glucose Monitoring Metrics
12 and 24 Weeks Pooleda

Baseline

Hours of data, mean (SD)

CGM Group
(n = 105)

Control
Group
(n = 53)

CGM Group
(n = 103)

Control
Group
(n = 53)

322 (50)

325 (51)

301 (41)

301 (54)

42 (7)

42 (7)

38 (6)

660 (179)

650 (170)

736 (206)

Mean Adjusted
Difference
(99% CI)b

P Valueb

42 (7)

−4 (−6 to −2)

<.001

650 (194)

77 (6 to 147)

.005

Prespecified secondary outcomes
Glucose variability: coefficient of
variation, mean (SD), %
Minutes per day in range 70-180 mg/dL,
mean (SD)
Hypoglycemia, median (IQR)
Minutes per day <70 mg/dL

65 (33 to 103)

72 (35 to 136)

43 (27 to 69)

80 (36 to 111)

.002

Minutes per day <60 mg/dL

32 (15 to 61)

39 (15 to 78)

20 (9 to 30)

40 (16 to 68)

.002

Minutes per day <50 mg/dL

13 (5 to 29)

18 (4 to 39)

6 (2 to 12)

20 (4 to 42)

.001

Hyperglycemia, median (IQR)
Minutes per day >180 mg/dL

687 (554 to 810)

725 (537 to 798)

638 (503 to 807)

740 (625 to 854)

.03

Minutes per day >250 mg/dL

301 (190 to 401)

269 (184 to 383)

223 (128 to 351)

347 (241 to 429)

<.001

Minutes per day >300 mg/dL

129 (66 to 201)

109 (71 to 204)

78 (36 to 142)

167 (89 to 226)

<.001

187 (27)

186 (30)

Prespecified exploratory outcome
Mean glucose, mean (SD), mg/dL

180 (27)

189 (25)

−9 (−19 to 0)

.01

Post hoc outcomes, median (IQR)c
Area above curve 70 mg/dL
Area under curve 180 mg/dL

0.5 (0.3 to 1.1)
34 (25 to 46)

0.7 (0.2 to 1.4)
33 (26 to 45)

SI Conversion: to convert glucose to mmol/L, multiply the values × 0.0555.
Excludes 2 participants in the CGM group with less than 72 hours of data
(a prespecified condition).

b

Treatment group comparisons made with analysis of covariance models,
adjusted for the corresponding baseline value, baseline hemoglobin A1c level,
and clinical site as a random effect, using pooled data from 12 and 24 weeks.
Because of skewed distributions for the hypoglycemia and hyperglycemia

variability favored the CGM group compared with the control
group (Table 3, eTable 5 in Supplement 2). In exploratory
analyses, hypoglycemia treatment group differences favored
the CGM group during both daytime and nighttime, but
hyperglycemia treatment group differences favoring the CGM
group were present only during the daytime (eTables 6 and 7
in Supplement 2).
Other Analyses
At 24 weeks, in post hoc analyses there were no significant differences between the CGM group and control group in median change in total daily insulin dose per kilogram of body
weight (–0.02 vs 0.03 U/kg; P = .23), median ratio of longacting to rapid-acting daily insulin dose (0.9 vs 1.0; P = .54),
proportion of participants with an increase in number of injections of rapid-acting insulin per day (26% vs 26%; P = .90),
or mean change in body weight (1.7 vs 0.7 kg; mean difference, 1.0 kg; 99% CI, –0.7 to 2.8; P = .12) (eTable 8 in
Supplement 2). Clarke Hypoglycemia Unawareness scores did
not differ between groups (mean difference, –0.1; 99% CI, –0.7
to 0.5; P = .64).

Severe Hypoglycemia and Other Adverse Events
Severe hypoglycemic events occurred in 2 participants in
each group (P = .67). There were no occurrences of diabetic
376

0.7 (0.2 to 1.3)
40 (31 to 51)

<.001
<.001

metrics (including area above the curve 70 mg/dL and area below the curve
180 mg/dL), these models were based on ranks using van der Waerden scores.
P < .01 was considered significant to account for multiple comparisons
(with 99% CI accordingly provided for the metrics that are approximately
normally distributed).

Abbreviations: CGM, continuous glucose monitoring; IQR, interquartile range.
a

0.3 (0.2 to 0.5)
27 (17 to 40)

c

Area above (the glucose) curve 70 mg/dL reflects both percentage and
severity of glucose values in the hypoglycemic range. Area under (the glucose)
curve 180 mg/dL is the analogous measure for hyperglycemia.

ketoacidosis. Other serious adverse events, unrelated to the
study intervention, occurred in 2 participants in the CGM group
and none in the control group (eTable 9 in Supplement 2).

CGM Satisfaction
In the CGM group, satisfaction with use of CGM was high, as
indicated by the mean (SD) score of 4.2 (0.4) on the CGM Satisfaction Survey, with mean (SD) scores of 4.2 (0.5) on the benefits subscale and 4.3 (0.5) on the subscale for lack of hassles
(eTable 10 in Supplement 2).

Discussion
Among adults with type 1 diabetes using multiple daily insulin injections, the use of CGM compared with usual care
resulted in a greater decrease in HbA1c level during 24 weeks.
The HbA1c benefit in the CGM group was consistently present
across the age range of 26 to 73 years, the baseline HbA1c
level range of 7.5% to 9.9%, and all education levels. In
addition, CGM use was associated with a high degree of
participant satisfaction with CGM, increased time with glucose concentrations between 70 and 180 mg/dL, decreased
time with glucose concentrations less than 70 mg/dL, and
decreased glycemic variability, measured with the coefficient
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of variation. The trial was not designed to demonstrate a benefit in reducing clinical severe hypoglycemia events, and the
low event rate in the control group precluded a meaningful
analysis. However, less biochemical hypoglycemia, as was
observed in the trial, has been associated with a lower risk for
subsequent severe hypoglycemic events14,15 and improved
quality of life.16-18
The amount of CGM use by the participants was high
(median CGM use 7 d/wk in month 6) despite a protocol approximating usual practice, with only 1 visit after week 4 and
no visits or other protocol-specified contacts between 12 and
24 weeks. The amount of use was similar to or greater than the
frequency of use in pump-using adults with type 1 diabetes in
previous trials and observational studies,2-5,19 which could be
related to CGM accuracy being significantly improved from the
generation of sensors in previous trials.20-22 The observed benefits of CGM occurred despite the CGM group’s having significantly less blood glucose meter testing per day than the control group.
The magnitude of benefit of CGM on HbA1c levels relative to control in this trial of insulin injection users is comparable to the magnitude of benefit of CGM observed in
pump users in previous randomized trials.2,4,5 This finding
was not a foregone conclusion. Insulin injection users have
less flexibility in adjusting their insulin delivery in response
to CGM glucose concentrations and trends than do pump
users. Basal insulin delivery for pump users is continuous,
can be programmed to vary at different times of the day,
and can be temporarily changed in response to decreasing
or increasing glucose concentrations or planned activities
such as exercise. In contrast, injection users have fixed basal
insulin based on the absorption of their long-acting insulin
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